1. Home
  2. VIRX

as 01-08-2025 4:00pm EST

$
0
1
2
3
4
5
6
7
8
9
.
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
-
$
0
1
2
3
4
5
6
7
8
9
.
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
-
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
.
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

;SMA (50)$0.18EMA (200)$0.41O: $0.20 H: $0.21 L: $0.18 C: $0.19 −0.02 (−8.44%)Elder Ray 0.01, −0.02
Founded: 2007 Country:
United States
United States
Employees: N/A City: CARDIFF
Market Cap: 7.0M IPO Year: N/A
Target Price: $5.00 AVG Volume (30 days): 2.2M
Analyst Decision: Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.10 EPS Growth: N/A
52 Week Low/High: $0.13 - $1.31 Next Earning Date: 11-13-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

VIRX Daily Stock ML Predictions

SELLHOLDBUYas of a day ago

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use